New combo therapy shows promise for tough blood cancers
NCT ID NCT03672539
First seen Nov 01, 2025 · Last updated May 08, 2026 · Updated 28 times
Summary
This study tests a combination of two chemotherapy drugs (CPX-351) plus a targeted antibody (gemtuzumab ozogamicin) in about 50 adults whose acute myeloid leukemia or high-risk myelodysplastic syndrome has returned or not responded to prior treatment. The goal is to see if the combo is safe and effective at shrinking or eliminating cancer cells. Participants receive the drugs in the hospital and are monitored for side effects and response.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROME are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.